As SGLT2 inhibitors have been demonstrated to reduce myocardial infarction size and cardiac remodeling, coupled with improved systolic function in both diabetic and non-diabetic animal models of myocardial infarction [11], whether dual SGLT1/2 inhibition by sotagliflozin has any beneficial effects is still unknown. The gene discussed is SLC5A2; the disease is myocardial infarction.